Eliana Merle
Stock Analyst at UBS
(3.39)
# 996
Out of 5,042 analysts
99
Total ratings
48.65%
Success rate
4.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Buy | $70 → $40 | $26.74 | +49.59% | 8 | Oct 23, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $54.26 | +51.12% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $2.48 | +262.90% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $3.95 | +507.59% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $29.53 | -69.52% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $421.50 | +24.08% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $35.07 | -42.97% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $202.00 | +51.98% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $54.48 | +109.25% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $463.43 | +18.68% | 3 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $22.81 | -47.39% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $3.20 | +150.00% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $5.36 | +2.61% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $9.21 | +128.01% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $58.56 | +19.54% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $28.17 | +56.19% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $38 | $14.79 | +156.93% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $53.77 | +102.72% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.71 | +28.65% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $54.48 | +30.32% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $14.23 | +96.77% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $9.14 | +31.29% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $6.20 | -51.61% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $105.66 | +23.98% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $18.69 | -73.25% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $7.77 | +131.66% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $61.01 | -31.16% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.14 | +97.49% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $13.03 | +260.71% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.67 | +84.54% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $32.02 | +318.49% | 3 | Aug 19, 2020 |
Moderna
Oct 23, 2025
Maintains: Buy
Price Target: $70 → $40
Current: $26.74
Upside: +49.59%
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $54.26
Upside: +51.12%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $2.48
Upside: +262.90%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.95
Upside: +507.59%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $29.53
Upside: -69.52%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $421.50
Upside: +24.08%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $35.07
Upside: -42.97%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $202.00
Upside: +51.98%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $54.48
Upside: +109.25%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $463.43
Upside: +18.68%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $22.81
Upside: -47.39%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $3.20
Upside: +150.00%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.36
Upside: +2.61%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $9.21
Upside: +128.01%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $58.56
Upside: +19.54%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $28.17
Upside: +56.19%
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $14.79
Upside: +156.93%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $53.77
Upside: +102.72%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.71
Upside: +28.65%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $54.48
Upside: +30.32%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $14.23
Upside: +96.77%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $9.14
Upside: +31.29%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $6.20
Upside: -51.61%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $105.66
Upside: +23.98%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $18.69
Upside: -73.25%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $7.77
Upside: +131.66%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $61.01
Upside: -31.16%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $11.14
Upside: +97.49%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $13.03
Upside: +260.71%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $8.67
Upside: +84.54%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $32.02
Upside: +318.49%